USFDA Pre-Approval Inspection at Indore facility concludes with 3 observations
USFDA carried out a Pre-Approval Inspection at the company's manufacturing facility at Pithampur, Indore, Madhya Pradesh.
By ScoutQuest · · 1 min read
- Inspection Type
- USFDA Pre-Approval Inspection
- Inspection Period
- October 15, 2026 to October 23, 2026
- Observations
- 3(three) observations in Form FDA 483
What the company informed the exchanges
- A Pre-Approval Inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's manufacturing facility at Plot no. 48, Smart Industrial Park, Near Natrip, Pithampur, District Dhar, Indore, Madhya Pradesh.
- The inspection was carried out from October 15, 2026 to October 23, 2026.
- Upon conclusion of the inspection, the company received 3(three) observations in Form FDA 483.
- The company stated that it will work closely with the USFDA and remains committed to addressing the observations comprehensively within the stipulated timeframe.
For a first-time reader
A Pre-Approval Inspection is an inspection the USFDA carries out in connection with a product approval application for a manufacturing site. Points noted during such an inspection are recorded in a form called Form FDA 483. The company has disclosed the number of observations, 3(three), and has said it will respond within the timeframe set for it.
What to watch
- The company's own statement is that it will address the observations; how and when that is done is the next thing to look for.
- The intimation does not set out what the observations relate to, so the scope cannot be judged from this letter alone.
- Any further communication from the company on the outcome of this inspection would be relevant to investors tracking this facility.
Also from Gufic Biosciences
Income Tax Appeal Allowed in Company's Favour; Rs. 4,33,36,680 Demand to Be Deleted
29 Sep 2026
Crisil Assigns Unsolicited ESG Rating of CRISIL ESG 62 (Strong) for FY 2025-26
28 Sep 2026
NSE Rejects Waiver; ₹1,72,000 Penalty to Be Paid by October 3, 2026
24 Sep 2026
More numbers
- Observations received in Form FDA 4833(three)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.